Onconova Logo BLUE.jpg
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
08 mars 2024 08h00 HE | Onconova Therapeutics, Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Onconova Logo BLUE.jpg
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
14 nov. 2023 16h05 HE | Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Logo BLUE.jpg
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
07 nov. 2023 16h05 HE | Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Logo BLUE.jpg
Onconova Expands Leadership Team with Two Key Appointments
24 oct. 2023 08h00 HE | Onconova Therapeutics, Inc.
Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D
Onconova Logo BLUE.jpg
Encouraging Rigosertib Data Presented at EADV as Late Breaker
12 oct. 2023 08h00 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Onconova Logo BLUE.jpg
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
28 sept. 2023 08h00 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Logo BLUE.jpg
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h00 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Logo BLUE.jpg
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
10 août 2023 16h05 HE | Onconova Therapeutics, Inc.
Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with...
Onconova Logo BLUE.jpg
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
03 août 2023 16h05 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...